ClinicalTrials.gg
CompletedNCT02243306Updated Apr 9, 2019Results posted

Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis

A Phase 1 interventional study of GSK1278863 in Anaemia, sponsored by GlaxoSmithKline. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-09.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
27th of 30
8 · median 76
Started
2014
with 2 others
Phase 1
10 of 30
none open now
Registered
10th of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 27th largest by enrollment, is one of 3 that started in 2014, is one of 10 in phase 1, and was the 10th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

GSK1278863 is an orally-active, novel small molecule agent which inhibits hypoxia-inducible factor (HIF) prolyl -4- hydroxylases (PHDs) and is in development for the treatment of anaemia associated with chronic kidney disease (CKD). As the kidney represents a major site of elimination for many drugs and their metabolites, and GSK1278863 will be administered to subjects with various stages of renal disease, it is important to characterize the pharmacokinetics in this target patient population. The purpose of this study is to characterize the pharmacokinetics of GSK1278863 and its metabolites in subjects with end stage renal disease (ESRD) undergoing peritoneal dialysis. This will be a repeat-dose, open-label, parallel-group study. Approximately 30 subjects with ESRD will be enrolled in two cohorts (15 subjects in each cohort) to ensure that 6 subjects on continuous ambulatory peritoneal dialysis (CAPD) (cohort 1) and 6 subjects on automated peritoneal dialysis APD (cohort 2) complete dosing and critical assessments. GSK1278863 will be administered once daily for 14 days. Primary pharmacokinetic assessments will be made on Days 1 and 14.

03

Conditions studied

  • Anaemia

Keywords

  • pharmacokinetics
  • Chronic kidney disease
  • peritoneal dialysis
  • hemoglobin
  • Anemia
  • GSK1278863
  • Prolyl hydroxylase inhibitor
  • erythropoiesis stimulating agents
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

SAFETY:

  • Satisfactory medical evaluation based upon medical history, medication history, physical examination, and clinical laboratory data obtained at the Screening visit. The determination of clinical significance will be made by the Investigator and the GlaxoSmithKline (GSK) Medical Monitor and will require that the finding is unlikely to introduce additional risk factors or interfere with the study procedures, or the integrity of the study.
  • interval (QTc) \<470 milliseconds (msec) OR QTc \<480 msec in subjects with Bundle Branch Block. These should be based on average of triplicate values obtained over a brief recording period at Screening and on Day -1 and the single reading on Day 17. The same QT correction formula should be used to determine inclusion and discontinuation for any individual subject throughout the study.
  • Vitamin B12 and folate above the lower limit of normal at Screening.
  • (AST), Alanine aminotransferase (ALT), and \<=1.5 x (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).

EFFICACY:

  • A subject is eligible to enroll and participate in this study if he/she has ESRD and is on peritoneal dialysis for at least 2 months with an average urine output of \<750 mL/daily with a combined weekly (urine and peritoneal dialysis output) Kt/V urea >1.7 measured at any time within last 3 months.
  • No history of peritoneal dialysis-associated peritonitis, peritoneal catheter tunnel (exit site) infection or leakage for at least 3 months before study.
  • Meets the following erythropoiesis stimulating agent (ESA) criteria: Is ESA naive (i.e., no ESA use within the previous 12 weeks of screening) OR agrees to discontinue ESA (if currently using ESA) for at least 7 days prior to first dose of GSK1278863 until completion of Follow-up visit (If the subject has a scheduled ESA interval which is \<=7 days, ESA treatment must be discontinued for at least 7 days prior to first dose of GSK1278863. If the subject has a scheduled ESA interval which is >7 days, ESA treatment must be discontinued for at least the scheduled interval length [e.g., if ESA interval is 14 days, then ESA must be discontinued for >=14 days] prior to the first dose of GSK1278863)
  • Has a value: For ESA naïve subjects: \<10.0 g/dL (UK site(s) only: \<=11.0 g/dL); For subjects receiving ongoing ESA treatment: \<=11.0 g/dL at Screening (UK site(s) only: \<=12.0 g/dL at Screening).

OTHER:

  • Subjects who are >=18 years of age at the time of Screening.
  • A female subject is eligible to participate if she is of: (a) , and agrees to use one of the methods described in the protocol. This criterion must be followed from the time of Screening until completion of the Follow-up Visit; (b) Non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or defined as 12 months of spontaneous amenorrhea (In questionable cases, a blood sample with simultaneous follicle stimulating hormone (FSH) 23.0-116.3 international units (IU)/litre (L) and estradiol \<=10 picograms (pg)/mL (or \<=37 picomoles [pmol]/L) is confirmatory). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods described in the protocol if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2 months must elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.
  • Body weight >45 kilograms (kg) and \<140 kg at Screening.
  • The subject is mentally and legally able to comply with the requirements and restrictions of the protocol and has provided signed prior to participation in any protocol-specific procedures, including Screening procedures.

Exclusion criteria

Exclusion Criteria:

SAFETY

  • A positive test for (HIV) antibody.
  • Uncontrolled hypertension (diastolic blood pressure [BP] >100 millimetres of mercury [mmHg] or systolic BP >170 mmHg) at Screening.
  • History of drug abuse or dependence within 6 months of the study.
  • History of sensitivity to GSK1278863, or its components thereof or a history of drug or other allergy that, in the opinion of the Investigator or GSK Medical Monitor, contraindicates their participation.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia (if the clinical research unit uses heparin to maintain intravenous cannula patency).
  • History of thrombosis defined as deep vein thrombosis, stroke, pulmonary embolism or other thrombosis related condition within 3 months prior to Screening.
  • History of myocardial infarction or acute coronary syndrome within 3 months prior to Screening.
  • History of stroke or within 3 months prior to Screening.
  • Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, and/or hepatic function that could interfere with the absorption, metabolism, and/or excretion of GSK1278863. Examples of conditions that could interfere with normal gastrointestinal anatomy or motility include gastrointestinal bypass surgery, partial or total gastrectomy, small bowel resection, vagotomy, malabsorption, Crohn's disease, ulcerative colitis, or celiac sprue. Examples of conditions that could interfere with hepatic function include Gilbert's syndrome.
  • Evidence of active peptic, duodenal or esophageal ulcer disease at Screening OR history of gastro-intestinal (GI) bleeding within 3 months prior to Screening.
  • Subjects with chronic inflammatory disease that could impact erythropoiesis (e.g. scleroderma, systemic lupus erythematosis, rheumatoid arthritis, celiac disease).
  • Subjects with a history of symptomatic right heart failure.
  • Subjects with Class III or Class IV heart failure, as defined by the (NYHA) functional classification system.
  • Active or diagnosis of malignancy within 5 years prior to Screening (excluding successfully treated basal or squamous cell carcinoma).
  • History of proliferative vascular eye disease (e.g., choroidal or retinal disease, such as neovascular age-related macular degeneration, proliferative diabetic retinopathy or macular edema) based upon having had an ophthalmologic exam within 12 months prior to the end of the Screening period (The screening period is from the screening visit until Day -1).
  • Pregnant females as determined by positive serum human chorionic gonadotropin (hCG) test at Screening or Day -1.
  • Lactating females.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period prior to first dose.
  • Consumption of red wine, grapefruit (juice), blood orange (juice), star fruit, onions, kale, broccoli, green beans, or apples from 7 days prior to the first dose of product until the Follow-up visit, unless in the opinion of the Investigator and GSK Medical Monitor this will not interfere with the study procedures and compromise subject safety.
  • Use or planned use of any prescription or non-prescription drugs that are prohibited within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of GSK1278863 until completion of the follow-up visit, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • The following medications are specifically prohibited for the duration of the study (from Screening to the follow-up visit at the end of the study): Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) with the exception of low dose (\<=325 mg/day) aspirin/acetylsalicylic acid. Occasional NSAID use is permitted; drugs and drugs used to treat malignancies (including at doses >10 mg prednisolone per day or equivalent) within 2 weeks of first dose of GSK1278863. Note: Failed transplant subjects back on peritoneal dialysis are eligible for participating in this study but should not be on immunosuppressive medications within 3 months prior to Screening.
  • The subject has participated in a clinical trial and has received an experimental investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).

EFFICACY:

  • The values of ferritin and transferrin within 3 months prior to Screening are: (a) transferrin saturation \<20%; (b) serum ferritin \<100 micrograms (mcg)/L

OTHER:

  • A positive pre-dosing drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines. A positive pre-dosing screen for medications that are prescribed to a renal subject for pre-existing condition(s), may be allowed if in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (approximately240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
  • History of regular use within 6 months of the study of tobacco- or nicotine-containing products in excess of 20 cigarettes per day or equivalent.
  • Unwillingness or inability to follow the procedures, or lifestyle and/or dietary restrictions outlined in the and as directed by site staff.
  • Subject is either an immediate family member of a participating Investigator, study coordinator, employee of an Investigator; or is a member of the staff conducting the study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Subjects on continuous ambulatory peritoneal dialysis (CAPD) will receive 5 mg of GSK1278863 orally, once daily for 14 days.

    Drug: GSK1278863

  • Experimental
    Cohort 2

    Subjects on automated peritoneal dialysis (APD) will receive 5 mg of GSK1278863 orally, once daily for 14 days

    Drug: GSK1278863

Interventions

  • Round, biconvex, white film coated tablet containing 5 mg GSK1278863.

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve (AUC) Over the Dosing Interval (AUC[0-tau]) of GSK1278863 and Its Metabolites

    Serial blood samples were collected from participants at indicated time points for Pharmacokinetic (PK) analysis of GSK1278863 and its metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401). Geometric mean and geometric coefficient of variation has been presented for all metabolites. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants. PK Population comprised of participants in the 'All Subjects' Population for whom a PK sample was obtained and analyzed.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post-dose on Day 1; Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose on Day 14

  2. AUC From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-inf]) of GSK1278863 and Its Metabolites

    Serial blood samples were collected from participants at indicated time points for PK analysis of GSK1278863 and its metabolites (GSK2487818 and GSK2531398). Geometric mean and geometric coefficient of variation has been presented for all metabolites. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post-dose on Day 1

  3. Maximum Observed Concentration (Cmax) of GSK1278863 and Its Metabolites

    Serial blood samples were collected from participants at indicated time points for PK analysis of GSK1278863 and its metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401). Geometric mean and geometric coefficient of variation has been presented for all metabolites. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post-dose on Day 1; Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose on Day 14

Secondary outcomes

  1. Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs)

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/birth defect, other situations, and is associated with liver injury and impaired liver function. Analysis was performed on All Subjects Population which comprised of all enrolled participants who received at least one dose of study treatment.

    Time frame: Up to Day 24

  2. Change From Baseline in Glucose, Calcium, Chloride, Carbon-dioxide (CO2), Potassium, Sodium and Urea Levels

    Blood samples were collected from participants to evaluate clinical chemistry parameters including glucose, calcium, chloride, CO2, potassium, sodium and urea. Change from Baseline in clinical chemistry parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

    Time frame: Baseline and Day 17

  3. Change From Baseline in Albumin and Protein Levels

    Blood samples were collected from participants to evaluate clinical chemistry parameters including albumin and protein. Change from Baseline in clinical chemistry parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

    Time frame: Baseline and Day 17

  4. Change From Baseline in Direct Bilirubin, Bilirubin, Creatinine and Urate Levels

    Blood samples were collected from participants to evaluate clinical chemistry parameters including direct bilirubin, bilirubin, creatinine and urate. Change from Baseline in clinical chemistry parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

    Time frame: Baseline and Day 17

  5. Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Gamma Glutamyl Aminotransferase (GGT) Levels

    Blood samples were collected from participants to evaluate clinical chemistry parameters including ALP, AST and GGT. Change from Baseline in clinical chemistry parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

    Time frame: Baseline and Day 17

  6. Change From Baseline in Alanine Aminotransferase (ALT) and Creatinine Kinase Levels

    Blood samples were collected from participants to evaluate clinical chemistry parameters including ALT and creatinine kinase. Change from Baseline in clinical chemistry parameters at Day 3, Day 7, Day 11, Day 14 and Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline and Day 3, 7, 11, 14, 17

  7. Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Levels

    Blood samples were collected from participants to evaluate clinical hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. NA indicates data is not available. Mean and standard deviation are presented. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

    Time frame: Baseline and Day 17

  8. Change From Baseline in Erythrocyte and Reticulocyte Levels

    Blood samples were collected from participants to evaluate clinical hematology parameters including erythrocyte and reticulocyte. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. NA indicates data is not available. Mean and standard deviation are presented. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

    Time frame: Baseline and Day 17

  9. Change From Baseline in Hematocrit Levels

    Blood samples were collected from participants to evaluate clinical hematology parameters including hematocrit. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

    Time frame: Baseline and Day 17

  10. Change From Baseline in Hemoglobin Levels

    Blood samples were collected from participants to evaluate clinical hematology parameters including hemoglobin. Change from Baseline in clinical hematology parameters at Day 3, Day 7, Day 11 and Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline and Day 3, 7, 11, 17

  11. Change From Baseline in Mean Corpuscular Hemoglobin Concentration (MCHC)

    Blood samples were collected from participants to evaluate clinical hematology parameters including MCHC. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

    Time frame: Baseline and Day 17

  12. Change From Baseline in Mean Corpuscular Volume (MCV)

    Blood samples were collected from participants to evaluate clinical hematology parameters including MCV. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

    Time frame: Baseline and Day 17

  13. Change From Baseline in Mean Corpuscular Hemoglobin (MCH) Levels

    Blood samples were collected from participants to evaluate clinical hematology parameters including MCH. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

    Time frame: Baseline and Day 17

  14. Number of Participants With Abnormal Electrocardiogram (ECG) Findings

    Single measurements of 12-lead ECG were obtained in supine position after at least 10 minutes of rest using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and corrected QT (QTc) interval. Participants with abnormal ECG findings at worst-case observation Carried Forward for triplicate measurements (WOCF) post-Baseline visit are presented. Only participants with data available at WOCF visit were analyzed.

    Time frame: Day 17

  15. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Vital sign measurements including SBP and DBP were taken in a supine position after at least 5 minutes of rest. Change from Baseline in SBP and DBP at Day 17 and Day 24 (follow-up) are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline, Day 17 and Day 24

  16. Change From Baseline in Pulse Rate

    Vital sign measurements including pulse rate were taken in a supine position after at least 5 minutes of rest. Change from Baseline in pulse rate at Day 17 and Day 24 (follow-up) are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline, Day 17 and Day 24

  17. Change From Baseline in Body Temperature

    Vital sign measurements including body temperature were taken in a supine position after at least 5 minutes of rest. Change from Baseline in body temperature at Day 17 and Day 24 (follow-up) are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline, Day 17 and Day 24

  18. Number of Participants With Abnormal Physical Examination Findings

    A complete physical examination was planned to include assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. This analysis was planned but not performed. Any significant finding was captured as an AE.

    Time frame: Up to Day 17

  19. Peritoneal Dialysis Clearance of GSK1278863 and Metabolites

    Peritoneal dialysate samples for PK analysis of GSK1278863 and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401) were collected. Peritoneal dialysis clearance of GSK1278863 and metabolites was calculated from Day 14 dialysate excretion data as total amount of analyte excreted over 24 hours divided by plasma AUC (0-tau). Geometric mean and geometric coefficient of variation are presented. NA indicates data is not available. Geometric coefficient of variation could not be calculated due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Day 14

  20. Terminal Phase Half-life (t 1/2) of GSK1278863 and Metabolites

    Serial blood samples were collected from participants at indicated time points for PK analysis of GSK1278863 and its metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403, GSK2531401). Geometric mean and geometric coefficient of variation have been presented for all metabolites. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants, which is indicated by NA. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post-dose on Day 1; Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose on Day 14

  21. Time of Occurrence of Cmax (Tmax) of GSK1278863 and Metabolites

    Serial blood samples were collected from participants at indicated time points for PK analysis of GSK1278863 and its metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401). Median and full range have been presented for all metabolites. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post-dose on Day 1; Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose on Day 14

  22. Accumulation Ratio of GSK1278863 and Metabolites

    The observed accumulation ratio was determined to estimate the extent of accumulation for GSK1278863 and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401) after repeat dosing. Accumulation ratio was calculated by using AUC (0-tau) values at Day 1 and Day 14. Analysis was performed using mixed effect model fitted with day (single and repeat dose) as fixed effect and participant as random effect. Mean ratio and 90% confidence intervals have been presented.

    Time frame: Day 1 and Day 14

  23. Time Invariance Ratio of GSK1278863 and Metabolites

    Time invariance ratio for GSK1278863 and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401) was calculated by analyzing AUC (0-inf) at Day 1 and AUC (0-tau) at Day 14. Analysis was performed using mixed effect model fitted with day (single and repeat dose) as fixed effect and participant as random effect. Mean ratio and 90% confidence intervals have been presented. NA indicates data is not available. Data could not be calculated due to insufficient data.

    Time frame: Day 1 and Day 14

  24. Plasma Concentration of Erythropoietin

    Serial blood samples were collected from participants at indicated time points to analyze plasma concentration of erythropoietin after repeat-dose administration of GSK1278863. Geometric mean and geometric coefficient of variation have been presented. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Pre-dose and 4, 8 ,12, 24 hours post-dose on Day 1 and Day 14; Pre-dose on Day 3, 7, 11

  25. Plasma Concentration of Hepcidin

    Serial blood samples were collected from participants at indicated time points to analyze plasma concentration of hepcidin after repeat-dose administration of GSK1278863. Geometric mean and geometric coefficient of variation have been presented. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Pre-dose and 4, 8 ,12, 24 hours post-dose on Day 1 and Day 14; Pre-dose on Day 3, 7, 11

07

Results

Posted Mar 11, 2019

Participant flow

This repeat-dose, pharmacokinetic (PK) study of GSK1278863 was conducted at two centers in the United States (US). Participants with End Stage Renal Disease (ESRD) undergoing continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) were included in this study.

Participant flow — Overall Study
MilestoneParticipants Undergoing CAPDParticipants Undergoing APD
Started17
Completed14
Not completed03
Withdrew: Adverse event01
Withdrew: Other: reached stopping criteria01
Withdrew: Physician decision01

Outcome measures

PrimaryArea Under the Concentration-time Curve (AUC) Over the Dosing Interval (AUC[0-tau]) of GSK1278863 and Its Metabolites

Serial blood samples were collected from participants at indicated time points for Pharmacokinetic (PK) analysis of GSK1278863 and its metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401). Geometric mean and geometric coefficient of variation has been presented for all metabolites. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants. PK Population comprised of participants in the 'All Subjects' Population for whom a PK sample was obtained and analyzed.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post-dose on Day 1; Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose on Day 14
Reported as:
Geometric mean · Hour into nanograms per milliliter
Area Under the Concentration-time Curve (AUC) Over the Dosing Interval (AUC[0-tau]) of GSK1278863 and Its Metabolites
Hour into nanograms per milliliterParticipants Undergoing CAPDParticipants Undergoing APD
GSK1278863; Day 1; n=1, 7184.9863 ± NA138.6511 ± 93.5
GSK1278863; Day 14; n=1, 4162.9366 ± NA131.2826 ± 78.8
GSK2391220; Day 1; n=1, 7245.8999 ± NA147.8039 ± 47.7
GSK2391220; Day 14; n=1, 4258.1199 ± NA162.0324 ± 50.7
GSK2487818; Day 1; n=1, 7116.2608 ± NA67.4130 ± 39.1
GSK2487818; Day 14; n=1, 4114.1857 ± NA59.6501 ± 51.5
GSK2506102; Day 1; n=1,659.0619 ± NA44.8180 ± 37.8
GSK2506102; Day 14; n=1, 482.9794 ± NA65.2188 ± 63.0
GSK2531398; Day 1; n=1, 797.0339 ± NA63.0979 ± 45.5
GSK2531398; Day 14; n=1, 497.6587 ± NA65.9664 ± 53.5
GSK2531403; Day 1; n=1, 7291.3067 ± NA170.4958 ± 45.5
GSK2531403; Day 14; n=1, 4360.2268 ± NA228.6081 ± 69.4
GSK2531401; Day 1; n=1, 6173.5919 ± NA104.2971 ± 48.6
GSK2531401; Day 14; n=1, 4242.0514 ± NA205.7281 ± 20.1
PrimaryAUC From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-inf]) of GSK1278863 and Its Metabolites

Serial blood samples were collected from participants at indicated time points for PK analysis of GSK1278863 and its metabolites (GSK2487818 and GSK2531398). Geometric mean and geometric coefficient of variation has been presented for all metabolites. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post-dose on Day 1
Reported as:
Geometric mean · Hour into nanograms per milliliter
AUC From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-inf]) of GSK1278863 and Its Metabolites
Hour into nanograms per milliliterParticipants Undergoing CAPDParticipants Undergoing APD
GSK1278863184.9888 ± NA138.6860 ± 93.6
GSK2487818117.2111 ± NA68.5089 ± 39.9
GSK2531398104.5268 ± NA73.9865 ± 51.3
PrimaryMaximum Observed Concentration (Cmax) of GSK1278863 and Its Metabolites

Serial blood samples were collected from participants at indicated time points for PK analysis of GSK1278863 and its metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401). Geometric mean and geometric coefficient of variation has been presented for all metabolites. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post-dose on Day 1; Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose on Day 14
Reported as:
Geometric mean · Nanograms per milliliter
Maximum Observed Concentration (Cmax) of GSK1278863 and Its Metabolites
Nanograms per milliliterParticipants Undergoing CAPDParticipants Undergoing APD
GSK1278863; Day 1; n= 1, 790.400 ± NA58.771 ± 96.7
GSK1278863; Day 14; n= 1, 457.800 ± NA30.303 ± 104.4
GSK2391220; Day 1; n= 1, 719.900 ± NA11.360 ± 44.3
GSK2391220; Day 14; n= 1, 420.500 ± NA10.966 ± 33.1
GSK2487818; Day 1; n= 1, 719.400 ± NA10.117 ± 25.7
GSK2487818; Day 14; n= 1, 418.400 ± NA7.262 ± 40.4
GSK2506102; Day 1; n= 1, 73.820 ± NA2.553 ± 42.7
GSK2506102; Day 14; n= 1, 45.050 ± NA3.590 ± 46.5
GSK2531398; Day 1; n= 1, 79.300 ± NA5.370 ± 44.2
GSK2531398; Day 14; n= 1, 49.220 ± NA4.857 ± 35.6
GSK2531403; Day 1; n= 1, 718.600 ± NA11.186 ± 36.7
GSK2531403; Day 14; n= 1, 423.400 ± NA13.267 ± 48.2
GSK2531401; Day 1; n= 1, 79.920 ± NA4.715 ± 78.4
GSK2531401; Day 14; n= 1, 413.300 ± NA10.404 ± 17.4
SecondaryNumber of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs)

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/birth defect, other situations, and is associated with liver injury and impaired liver function. Analysis was performed on All Subjects Population which comprised of all enrolled participants who received at least one dose of study treatment.

Time frame:
Up to Day 24
Reported as:
Number · Participants
Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs)
ParticipantsParticipants Undergoing CAPDParticipants Undergoing APD
Non-serious AEs15
SAEs00
SecondaryChange From Baseline in Glucose, Calcium, Chloride, Carbon-dioxide (CO2), Potassium, Sodium and Urea Levels

Blood samples were collected from participants to evaluate clinical chemistry parameters including glucose, calcium, chloride, CO2, potassium, sodium and urea. Change from Baseline in clinical chemistry parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

Time frame:
Baseline and Day 17
Reported as:
Mean · Millimoles per liter
Change From Baseline in Glucose, Calcium, Chloride, Carbon-dioxide (CO2), Potassium, Sodium and Urea Levels
Millimoles per literParticipants Undergoing CAPDParticipants Undergoing APD
Glucose-0.10 ± NA0.27 ± 7.191
Calcium0.360 ± NA0.040 ± 0.2026
Chloride-2.0 ± NA-1.3 ± 2.99
CO20.0 ± NA0.3 ± 5.19
Potassium0.20 ± NA-0.45 ± 0.580
Sodium2.0 ± NA-1.5 ± 3.70
Urea12.50 ± NA-0.38 ± 3.568
SecondaryChange From Baseline in Albumin and Protein Levels

Blood samples were collected from participants to evaluate clinical chemistry parameters including albumin and protein. Change from Baseline in clinical chemistry parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

Time frame:
Baseline and Day 17
Reported as:
Mean · Gram per liter (g/L)
Change From Baseline in Albumin and Protein Levels
Gram per liter (g/L)Participants Undergoing CAPDParticipants Undergoing APD
Albumin3.0 ± NA-1.3 ± 3.20
Protein5.0 ± NA-2.0 ± 5.48
SecondaryChange From Baseline in Direct Bilirubin, Bilirubin, Creatinine and Urate Levels

Blood samples were collected from participants to evaluate clinical chemistry parameters including direct bilirubin, bilirubin, creatinine and urate. Change from Baseline in clinical chemistry parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

Time frame:
Baseline and Day 17
Reported as:
Mean · Micromoles per liter
Change From Baseline in Direct Bilirubin, Bilirubin, Creatinine and Urate Levels
Micromoles per literParticipants Undergoing CAPDParticipants Undergoing APD
Direct bilirubin0.0 ± NA-0.5 ± 1.91
Bilirubin-2.0 ± NA0.5 ± 1.00
Creatinine13.30 ± NA-119.12 ± 312.679
Urate-30.0 ± NA-25.0 ± 87.37
SecondaryChange From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Gamma Glutamyl Aminotransferase (GGT) Levels

Blood samples were collected from participants to evaluate clinical chemistry parameters including ALP, AST and GGT. Change from Baseline in clinical chemistry parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

Time frame:
Baseline and Day 17
Reported as:
Mean · International unit per liter (IU/L)
Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Gamma Glutamyl Aminotransferase (GGT) Levels
International unit per liter (IU/L)Participants Undergoing CAPDParticipants Undergoing APD
ALP5.0 ± NA-0.5 ± 16.52
AST-1.0 ± NA-3.3 ± 3.77
GGT0.0 ± NA-6.3 ± 8.77
SecondaryChange From Baseline in Alanine Aminotransferase (ALT) and Creatinine Kinase Levels

Blood samples were collected from participants to evaluate clinical chemistry parameters including ALT and creatinine kinase. Change from Baseline in clinical chemistry parameters at Day 3, Day 7, Day 11, Day 14 and Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline and Day 3, 7, 11, 14, 17
Reported as:
Mean · IU/L
Change From Baseline in Alanine Aminotransferase (ALT) and Creatinine Kinase Levels
IU/LParticipants Undergoing CAPDParticipants Undergoing APD
ALT; Day 3; n= 1, 6-3.0 ± NA-0.7 ± 3.98
ALT; Day 7; n= 1, 4-7.0 ± NA-2.5 ± 5.32
ALT; Day 11; 1, 4-9.0 ± NA-3.5 ± 5.80
ALT; Day 14; n= 1, 4-7.0 ± NA-0.8 ± 3.86
ALT; Day 17; n= 1, 4-7.0 ± NA-1.0 ± 6.06
Creatine kinase; Day 3; n= 1, 6-12.0 ± NA-99.7 ± 161.17
Creatine kinase; Day 7; n= 1, 4-12.0 ± NA-137.8 ± 230.33
Creatine kinase; Day 11; n= 1, 41.0 ± NA-135.8 ± 273.85
Creatine kinase; Day 14; n= 1, 49.0 ± NA-183.5 ± 247.13
Creatine kinase; Day 17; n= 1, 4-2.0 ± NA-201.5 ± 191.83
SecondaryChange From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Levels

Blood samples were collected from participants to evaluate clinical hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. NA indicates data is not available. Mean and standard deviation are presented. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

Time frame:
Baseline and Day 17
Reported as:
Mean · 10^9 cells/liter
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Levels
10^9 cells/literParticipants Undergoing CAPDParticipants Undergoing APD
Basophils-0.020 ± NA0.010 ± 0.0200
Eosinophils-0.010 ± NA0.060 ± 0.0804
Lymphocytes0.260 ± NA-0.138 ± 0.3974
Monocytes0.230 ± NA0.060 ± 0.3389
Neutrophils1.350 ± NA-0.365 ± 1.1957
Platelets42.0 ± NA-21.0 ± 35.92
Leukocytes1.80 ± NA-0.35 ± 1.008
SecondaryChange From Baseline in Erythrocyte and Reticulocyte Levels

Blood samples were collected from participants to evaluate clinical hematology parameters including erythrocyte and reticulocyte. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. NA indicates data is not available. Mean and standard deviation are presented. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

Time frame:
Baseline and Day 17
Reported as:
Mean · 10^12 cells/liter
Change From Baseline in Erythrocyte and Reticulocyte Levels
10^12 cells/literParticipants Undergoing CAPDParticipants Undergoing APD
Erythrocytes0.00 ± NA-0.05 ± 0.412
Reticulocytes0.02840 ± NA-0.00165 ± 0.044431
SecondaryChange From Baseline in Hematocrit Levels

Blood samples were collected from participants to evaluate clinical hematology parameters including hematocrit. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

Time frame:
Baseline and Day 17
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematocrit Levels
Proportion of red blood cells in bloodParticipants Undergoing CAPDParticipants Undergoing APD
Change From Baseline in Hematocrit Levels0.0070 ± NA-0.0100 ± 0.03880
SecondaryChange From Baseline in Hemoglobin Levels

Blood samples were collected from participants to evaluate clinical hematology parameters including hemoglobin. Change from Baseline in clinical hematology parameters at Day 3, Day 7, Day 11 and Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline and Day 3, 7, 11, 17
Reported as:
Mean · g/L
Change From Baseline in Hemoglobin Levels
g/LParticipants Undergoing CAPDParticipants Undergoing APD
Day 3; n= 1, 77.0 ± NA3.1 ± 11.96
Day 7; n= 1, 54.0 ± NA-2.2 ± 9.78
Day 11; n= 1, 50.0 ± NA-3.2 ± 8.14
Day 17; n= 1, 45.0 ± NA-1.3 ± 13.74
SecondaryChange From Baseline in Mean Corpuscular Hemoglobin Concentration (MCHC)

Blood samples were collected from participants to evaluate clinical hematology parameters including MCHC. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

Time frame:
Baseline and Day 17
Reported as:
Mean · g/L
Change From Baseline in Mean Corpuscular Hemoglobin Concentration (MCHC)
g/LParticipants Undergoing CAPDParticipants Undergoing APD
Change From Baseline in Mean Corpuscular Hemoglobin Concentration (MCHC)8.0 ± NA6.3 ± 3.86
SecondaryChange From Baseline in Mean Corpuscular Volume (MCV)

Blood samples were collected from participants to evaluate clinical hematology parameters including MCV. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

Time frame:
Baseline and Day 17
Reported as:
Mean · Femtoliter
Change From Baseline in Mean Corpuscular Volume (MCV)
FemtoliterParticipants Undergoing CAPDParticipants Undergoing APD
Change From Baseline in Mean Corpuscular Volume (MCV)1.0 ± NA-1.5 ± 1.73
SecondaryChange From Baseline in Mean Corpuscular Hemoglobin (MCH) Levels

Blood samples were collected from participants to evaluate clinical hematology parameters including MCH. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.

Time frame:
Baseline and Day 17
Reported as:
Mean · Picograms
Change From Baseline in Mean Corpuscular Hemoglobin (MCH) Levels
PicogramsParticipants Undergoing CAPDParticipants Undergoing APD
Change From Baseline in Mean Corpuscular Hemoglobin (MCH) Levels1.00 ± NA-0.02 ± 0.866
SecondaryNumber of Participants With Abnormal Electrocardiogram (ECG) Findings

Single measurements of 12-lead ECG were obtained in supine position after at least 10 minutes of rest using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and corrected QT (QTc) interval. Participants with abnormal ECG findings at worst-case observation Carried Forward for triplicate measurements (WOCF) post-Baseline visit are presented. Only participants with data available at WOCF visit were analyzed.

Time frame:
Day 17
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
ParticipantsParticipants Undergoing CAPDParticipants Undergoing APD
Number of Participants With Abnormal Electrocardiogram (ECG) Findings03
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Vital sign measurements including SBP and DBP were taken in a supine position after at least 5 minutes of rest. Change from Baseline in SBP and DBP at Day 17 and Day 24 (follow-up) are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline, Day 17 and Day 24
Reported as:
Mean · Millimeters of mercury
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeters of mercuryParticipants Undergoing CAPDParticipants Undergoing APD
SBP; Day 17; n= 1, 512.0 ± NA-10.4 ± 10.06
SBP; follow-up; n= 1, 724.0 ± NA-10.0 ± 12.46
DBP; Day 17; n= 1, 510.0 ± NA-3.4 ± 13.07
DBP; follow-up; n= 1, 7-4.0 ± NA0.1 ± 12.52
SecondaryChange From Baseline in Pulse Rate

Vital sign measurements including pulse rate were taken in a supine position after at least 5 minutes of rest. Change from Baseline in pulse rate at Day 17 and Day 24 (follow-up) are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline, Day 17 and Day 24
Reported as:
Mean · Beats per minute
Change From Baseline in Pulse Rate
Beats per minuteParticipants Undergoing CAPDParticipants Undergoing APD
Day 17; n= 1, 5-9.0 ± NA-5.6 ± 9.53
Follow-up; n= 1, 7-6.0 ± NA-7.0 ± 11.58
SecondaryChange From Baseline in Body Temperature

Vital sign measurements including body temperature were taken in a supine position after at least 5 minutes of rest. Change from Baseline in body temperature at Day 17 and Day 24 (follow-up) are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline, Day 17 and Day 24
Reported as:
Mean · Degree celsius
Change From Baseline in Body Temperature
Degree celsiusParticipants Undergoing CAPDParticipants Undergoing APD
Day 17; n= 1, 5-0.10 ± NA-0.20 ± 0.648
Follow-up; n= 1, 7-0.90 ± NA-0.30 ± 0.548
SecondaryNumber of Participants With Abnormal Physical Examination Findings

A complete physical examination was planned to include assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. This analysis was planned but not performed. Any significant finding was captured as an AE.

Time frame:
Up to Day 17

No measurements were reported for this outcome.

SecondaryPeritoneal Dialysis Clearance of GSK1278863 and Metabolites

Peritoneal dialysate samples for PK analysis of GSK1278863 and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401) were collected. Peritoneal dialysis clearance of GSK1278863 and metabolites was calculated from Day 14 dialysate excretion data as total amount of analyte excreted over 24 hours divided by plasma AUC (0-tau). Geometric mean and geometric coefficient of variation are presented. NA indicates data is not available. Geometric coefficient of variation could not be calculated due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Day 14
Reported as:
Geometric mean · Milliliter per hour
Peritoneal Dialysis Clearance of GSK1278863 and Metabolites
Milliliter per hourParticipants Undergoing CAPDParticipants Undergoing APD
GSK1278863; n= 1, 012.07 ± NA—
GSK2391220; n= 1, 4154.68 ± NA31.68 ± 165.5
GSK2487818; n= 1, 3124.40 ± NA13.08 ± 195.3
GSK2506102; n= 1, 4167.89 ± NA40.05 ± 169.7
GSK2531398; n= 1, 4151.29 ± NA28.39 ± 177.5
GSK2531403; n= 1, 4155.75 ± NA36.18 ± 183.2
GSK2531401; n= 1, 4201.80 ± NA48.89 ± 199.7
SecondaryTerminal Phase Half-life (t 1/2) of GSK1278863 and Metabolites

Serial blood samples were collected from participants at indicated time points for PK analysis of GSK1278863 and its metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403, GSK2531401). Geometric mean and geometric coefficient of variation have been presented for all metabolites. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants, which is indicated by NA. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post-dose on Day 1; Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose on Day 14
Reported as:
Geometric mean · Hours
Terminal Phase Half-life (t 1/2) of GSK1278863 and Metabolites
HoursParticipants Undergoing CAPDParticipants Undergoing APD
GSK1278863; Day 1; n= 1, 71.6256 ± NA1.9870 ± 25.8
GSK1278863; Day 14; n= 1, 41.8088 ± NA2.5312 ± 35.7
GSK2391220; Day 14; n= 1, 49.2225 ± NA10.2882 ± 27.2
GSK2487818; Day 1; n=1, 73.6560 ± NA3.3612 ± 22.7
GSK2487818; Day 14; n= 1, 42.9958 ± NA3.8955 ± 25.3
GSK2506102; Day 14; n= 1,416.2000 ± NA17.7692 ± 65.4
GSK2531398; Day 1; n=1, 75.7900 ± NA7.0659 ± 35.9
GSK2531398; Day 14; n= 1, 45.8275 ± NA7.3088 ± 40.0
GSK2531403; Day 14; n= 1, 413.0606 ± NA14.5877 ± 43.5
GSK2531401; Day 14; n= 1, 420.7794 ± NA26.9981 ± 54.2
SecondaryTime of Occurrence of Cmax (Tmax) of GSK1278863 and Metabolites

Serial blood samples were collected from participants at indicated time points for PK analysis of GSK1278863 and its metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401). Median and full range have been presented for all metabolites. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post-dose on Day 1; Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose on Day 14
Reported as:
Median · Hour
Time of Occurrence of Cmax (Tmax) of GSK1278863 and Metabolites
HourParticipants Undergoing CAPDParticipants Undergoing APD
GSK1278863; Day 1; n=1, 70.50 (0.5 to 0.5)1.00 (1.0 to 3.0)
GSK1278863; Day 14; n= 1, 42.00 (2.0 to 2.0)2.00 (1.0 to 4.0)
GSK2391220; Day 1; n= 1, 73.00 (3.0 to 3.0)4.00 (3.0 to 8.0)
GSK2391220; Day 14; n= 1, 44.00 (4.0 to 4.0)5.00 (4.0 to 6.0)
GSK2487818; Day 1; n= 1, 73.00 (3.0 to 3.0)4.00 (2.0 to 6.0)
GSK2487818; Day 14; n= 1, 43.00 (3.0 to 3.0)4.00 (3.0 to 4.0)
GSK2506102; Day 1; n=1, 74.00 (4.0 to 4.0)8.00 (3.0 to 12.0)
GSK2506102; Day 14; n= 1, 44.00 (4.0 to 4.0)5.00 (4.0 to 6.0)
GSK2531398; Day 1; n= 1,74.00 (4.0 to 4.0)4.00 (3.0 to 8.0)
GSK2531398; Day 14; n= 1, 44.00 (4.0 to 4.0)5.00 (4.0 to 6.0)
GSK2531403; Day 1; n= 1, 76.00 (6.0 to 6.0)6.00 (2.0 to 8.0)
GSK2531403; Day 14; n= 1, 44.00 (4.0 to 4.0)6.00 (4.0 to 6.0)
GSK2531401; Day 1; n= 1, 78.00 (8.0 to 8.0)8.00 (3.0 to 12.0)
GSK2531401; Day 14; n= 1, 48.00 (8.0 to 8.0)9.00 (6.0 to 12.0)
SecondaryAccumulation Ratio of GSK1278863 and Metabolites

The observed accumulation ratio was determined to estimate the extent of accumulation for GSK1278863 and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401) after repeat dosing. Accumulation ratio was calculated by using AUC (0-tau) values at Day 1 and Day 14. Analysis was performed using mixed effect model fitted with day (single and repeat dose) as fixed effect and participant as random effect. Mean ratio and 90% confidence intervals have been presented.

Time frame:
Day 1 and Day 14
Reported as:
Mean · Ratio of AUC
Accumulation Ratio of GSK1278863 and Metabolites
Ratio of AUCAll Participants
GSK12788630.896 (0.645 to 1.244)
GSK23912201.176 (1.043 to 1.326)
GSK24878181.019 (0.944 to 1.100)
GSK25061021.581 (1.200 to 2.081)
GSK25313981.116 (1.015 to 1.228)
GSK25314031.415 (1.131 to 1.771)
GSK25314011.948 (1.301 to 2.918)
SecondaryTime Invariance Ratio of GSK1278863 and Metabolites

Time invariance ratio for GSK1278863 and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401) was calculated by analyzing AUC (0-inf) at Day 1 and AUC (0-tau) at Day 14. Analysis was performed using mixed effect model fitted with day (single and repeat dose) as fixed effect and participant as random effect. Mean ratio and 90% confidence intervals have been presented. NA indicates data is not available. Data could not be calculated due to insufficient data.

Time frame:
Day 1 and Day 14
Reported as:
Mean · Ratio of AUC
Time Invariance Ratio of GSK1278863 and Metabolites
Ratio of AUCAll Participants
GSK1278863; n= 80.896 (0.645 to 1.244)
GSK2487818; n= 81.007 (0.932 to 1.087)
GSK2531398; n= 80.986 (0.941 to 1.033)
SecondaryPlasma Concentration of Erythropoietin

Serial blood samples were collected from participants at indicated time points to analyze plasma concentration of erythropoietin after repeat-dose administration of GSK1278863. Geometric mean and geometric coefficient of variation have been presented. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Pre-dose and 4, 8 ,12, 24 hours post-dose on Day 1 and Day 14; Pre-dose on Day 3, 7, 11
Reported as:
Geometric mean · IU/L
Plasma Concentration of Erythropoietin
IU/LParticipants Undergoing CAPDParticipants Undergoing APD
Day 1; pre-dose; n= 1, 713.860 ± NA11.363 ± 124.9
Day 1; 4 hours; n= 1, 711.590 ± NA14.494 ± 127.1
Day 1; 8 hours; n= 1, 723.540 ± NA36.257 ± 96.0
Day 1; 12 hours; n= 1, 732.210 ± NA32.629 ± 112.4
Day 1; 24 hours; n= 1, 713.570 ± NA13.005 ± 127.5
Day 3; pre-dose; n= 1, 610.030 ± NA15.452 ± 152.9
Day 7; pre-dose; n= 1, 35.070 ± NA8.023 ± 66.4
Day 11; pre-dose; n= 1, 38.690 ± NA9.466 ± 69.8
Day 14; pre-dose; n= 1, 49.490 ± NA6.036 ± 71.2
Day 14; 4 hours; n= 1, 312.660 ± NA7.674 ± 34.9
Day 14; 8 hours; n= 1, 430.220 ± NA19.313 ± 81.6
Day 14; 12 hours; n= 1, 421.050 ± NA25.745 ± 74.6
Day 14; 24 hours; n= 1, 46.590 ± NA6.735 ± 88.1
SecondaryPlasma Concentration of Hepcidin

Serial blood samples were collected from participants at indicated time points to analyze plasma concentration of hepcidin after repeat-dose administration of GSK1278863. Geometric mean and geometric coefficient of variation have been presented. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Pre-dose and 4, 8 ,12, 24 hours post-dose on Day 1 and Day 14; Pre-dose on Day 3, 7, 11
Reported as:
Geometric mean · Micrograms per liter
Plasma Concentration of Hepcidin
Micrograms per literParticipants Undergoing CAPDParticipants Undergoing APD
Day 1; pre-dose; n= 1, 71143.00 ± NA863.21 ± 100.3
Day 1; 4 hours; n= 1, 71286.00 ± NA922.86 ± 108.3
Day 1; 8 hours; n= 1, 71427.10 ± NA760.14 ± 80.1
Day 1; 12 hours; n= 1, 71318.00 ± NA812.62 ± 86.1
Day 1; 24 hours; n= 1, 7867.20 ± NA802.06 ± 93.5
Day 3; pre-dose; n= 1, 61021.70 ± NA819.17 ± 90.7
Day 7; pre-dose; n= 1, 4825.30 ± NA839.42 ± 81.5
Day 11; pre-dose; n= 1, 4852.90 ± NA800.77 ± 91.3
Day 14; pre-dose; n= 1, 4734.30 ± NA768.33 ± 86.8
Day 14; 4 hours; n= 1, 4847.90 ± NA782.59 ± 81.9
Day 14; 8 hours; n= 1, 4809.90 ± NA738.96 ± 79.2
Day 14; 12 hours; n= 1, 4705.70 ± NA757.72 ± 87.9
Day 14; 24 hours; n= 1, 4801.30 ± NA733.66 ± 81.9

Adverse events

Collected over SAEs and non-SAEs are presented from the start of study treatment up to Day 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants Undergoing CAPD0/1 (0%)0/1 (0%)1/1 (100%)
Participants Undergoing APD0/7 (0%)0/7 (0%)5/7 (71.4%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventParticipants Undergoing CAPDParticipants Undergoing APD
DiarrhoeaGastrointestinal disorders1/11/7
MyalgiaMusculoskeletal and connective tissue disorders1/11/7
Neck painMusculoskeletal and connective tissue disorders1/10/7
HypoglycaemiaMetabolism and nutrition disorders0/12/7
NauseaGastrointestinal disorders0/11/7
VomitingGastrointestinal disorders0/11/7
Face oedemaGeneral disorders0/11/7
FatigueGeneral disorders0/11/7
PyrexiaGeneral disorders0/11/7
InfluenzaInfections and infestations0/11/7

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Participants Undergoing CAPDParticipants Undergoing APDTotal
Mean44.0 ± NA57.4 ± 12.0155.8 ± 12.09
Sex: Female, Male
Sex: Female, Male(Participants)Participants Undergoing CAPDParticipants Undergoing APDTotal
Female022
Male156
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Participants Undergoing CAPDParticipants Undergoing APDTotal
Race customized — American Indian or Alaska Native Heritage011
Race customized — Black or African American Heritage033
Race customized — White- White/Caucasian/European Heritage134
08

Study locations

2 sites
  • GSK Investigational Site
    Lakewood, Colorado 80228, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55404, United States
09

References and documents

Publications

  • Caltabiano S, Cizman B, Burns O, Mahar KM, Johnson BM, Ramanjineyulu B, Serbest G, Cobitz AR. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure. Clin Kidney J. 2019 Feb 18;12(5):693-701. doi: 10.1093/ckj/sfz013. eCollection 2019 Oct. PubMed 31583094 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in May 2017, 30 months.

Results were first posted in Mar 2019, 1 year 10 months after primary completion.

Of 34 industry-sponsored phase 1 interventional studies under Anemia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 30. This study's 30 months is above that.

Counting every sponsor, half of 48 studies reached it within 12 months; a quarter within 3 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2014
First posted
Sep 17, 2014
StartActual
Oct 24, 2014
Primary completionActual
May 10, 2017
CompletionActual
May 10, 2017
Results first posted
Mar 11, 2019
Last update
Apr 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02243306
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 17, 2014
Start date
Oct 24, 2014
Primary completion
May 10, 2017
Completion
May 10, 2017
Results posted
Mar 11, 2019
Last update
Apr 9, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion